Special Edition

Special Edition

Early-Phase Trials of HDM201 Show Promise in Leukemias

The HDM2 inhibitor HDM201 induced remissions in patients with leukemia or solid tumors in two ongoing clinical trials presented at the 2017 AACR Annual...

Real-World Study Suggests Acquired Hemophilia A Patients Can Receive Lower Doses of Recombinant Porcine...

A retrospective study presented at the Thrombosis and Hemostasis Societies of North America 2016 Summit provided real-world data on recombinant porcine factor VIII (rpFVIII)...
On location

Bortezomib Leads to More Complete Remissions in Patients With High-Risk Follicular Lymphoma

With few monotherapy treatment options available for patients with high-risk follicular lymphoma (FL), investigators are evaluating combinations with agents approved for other indications to...

A Look at Patient Outcomes in Overlapping Multiple Myeloma and Chronic Lymphocytic Leukemia

Though multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) have overlapping epidemiologic features and originate from mature B cells, the simultaneous occurrence of both...
On location

Masitinib Improves Symptom Burden, Responses in Patients with Severe Systemic Mastocytosis

Masitinib, a selective oral tyrosine kinase inhibitor (TKI) targeting wild-type KIT, LYN, and FYN, reduced the severity of a diverse range of symptoms in...
On location

Long-Term Safety and Efficacy Data for Pacritinib in Myelofibrosis: Updates from PERSIST-1

In two updated analyses from the phase III PERSIST-1 study presented at the 2016 ASCO Annual Meeting, authors presented new data about the safety...
On location

Examining Mogamulizumab for T-Cell Leukemia and Lymphoma

Patients with adult T-cell leukemia and lymphoma (ATLL), a rare T-cell malignancy caused by the human T lymphotropic virus type 1 (HTLV-1), have limited...

Policy Updates

ASH Calls for Payment Innovation in Rare Diseases Such as Sickle Cell Disease The Center for Medicare and Medicaid Innovation (CMMI), a branch of the...

SL-401 Improves Overall Response Rate for Blastic Plasmacytoid Dendritic Cell Neoplasm

SL-401, a targeted therapy directed to the interleukin-3 receptor CD123, was shown to improve overall response (ORR) and complete response (CR) rates in patients...

FDA Update: Recent Approvals and Designations for Orphan Drugs

In instances where an investigational drug would be the first available treatment or would have advantages over existing treatments, the U.S. Food and Drug...
Advertisement

Current Issue

June 2019, Volume 5, Issue 7

This issue features a debate about new treatment options for beta-thalassemia, a look at what’s driving skyrocketing drug prices in myeloma, and more.